Phaseline

Targets › RHOA

RHOA (Transforming protein RhoA): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout Dec 2027.

Small GTPase which cycles between an active GTP-bound and an inactive GDP-bound state. Mainly associated with cytoskeleton organization, in active state binds to a variety of effector proteins to regulate cellular responses such as cytoskeletal dynamics, cell migration and cell cycle. (UniProt, P61586)

Open in Phaseline: the race on RHOA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
IVIEW TherapeuticsGVB-2001
Self-complementary adeno-associated viral vector (scAAV) delivering dominant-negative RhoA
RHOAPhase 1Primary Open-Angle Glaucoma (POAG)Dec 2027

Conditions

Primary Open-Angle Glaucoma (POAG) (1)

Modalities

small molecule (1)

Companies

IVIEW Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.